Bristol-Myers Squibb will be reacquiring the rights to ASLAN002, a gastric and breast cancer drug, for several APAC markets.
The novel pyrosequencing platform can perform real-time sequencing for quicker medical decision-making.
Bristol-Myers Squibb has awarded US$3.5 million in grants to tackle the 'silent epidemic' of hepatitis in India and China.
Bristol-Myers Squibb and Kyowa Hakko Kirin will commercialize Coniel, a calcium channel blocker for the treatment of hypertension and angina pectoris, in China.
Samsung BioLogics will manufacture a commercial antibody cancer drug for Bristol-Myers Squibb at its Songdo Incheon plant in South Korea.
BMS and Simcere will co-develop and co-commercialize the subcutaneous formulation of Orencia® for the treatment of rheumatoid arthritis in China.
To mark World Hepatitis Day 2012, the Bristol-Myers Squibb Foundation has awarded four new grants focused on Hepatitis B and Hepatitis C research in China and India.
Bristol-Myers Squibb Company and Tsinghua University of Beijing, China, announced this Monday the formation of a multi-year research partnership.
The Bristol-Myers Squibb Foundation has awarded three new grants to further research into hepatitis B and C in China and India.
BMS and Simcere Pharma have agreed to co-develop BMS-795311, a preclinical small molecule inhibitor of the cholesteryl ester transfer protein.